On this page
What evidence should an RMAT designation request contain?
Connect an eligible regenerative medicine product to a serious condition and preliminary clinical evidence showing potential to address an unmet medical need. Explain the actual patients, treatment, endpoints, follow-up, safety and limitations, and establish relevance to the product intended for development. Submit through an initial or existing IND in an eligible status; RMAT designation does not establish approval or confirmed durable benefit.
Before you begin
FDA RMAT designation for eligible regenerative medicine therapies; not a general expedited designation for every advanced therapy.
What you will prepare: An IND-linked request with a transparent clinical-evidence and eligibility argument.
Address all three eligibility questions
Describe why the product falls within the relevant regenerative-medicine scope; why the disease or condition is serious or life-threatening; and how preliminary clinical evidence indicates potential to address an unmet medical need. Use the actual product classification and indication rather than relying on the marketing term “advanced therapy.” Products regulated solely under the specified section 361/Part 1271 framework are excluded from the statutory RMAT definition described by FDA.
The request is made with an initial IND or as an amendment to an existing IND. FDA states it will not grant designation when the IND is on hold or is placed on hold during the designation review. Confirm actual IND status before claiming readiness.
Show what the preliminary clinical evidence can support
Collect the study identifiers, population, treatment exposure, endpoints, follow-up, results and relevant safety findings. Explain the current treatment landscape and the unmet need in the proposed population. Connect each promising observation to the underlying clinical evidence and its limitations: sample size, missing data, lack of control, selection bias and durability where relevant.
Nonclinical plausibility alone does not meet the preliminary-clinical-evidence criterion. Conversely, do not invent a universal minimum trial size or requirement for one particular trial design. Explain why the available evidence is informative for this therapy and condition and preserve uncertainty rather than extrapolating an early response into established long-term benefit.
Write a focused request with the right context
An editorial order is: request/application identity; product and eligibility; serious condition/unmet need; clinical-evidence summary with report references; safety/limitations; development context; attachments and requested FDA action. Make the designation request conspicuous in the cover letter according to FDA's instructions. Do not describe it as licensure or assurance of accelerated approval.
Fictional editorial exercise: an early uncontrolled study reports a short-term response, but the draft says the therapy produces durable disease reversal. Replace that claim with the observed endpoint and follow-up, and explain the uncertainty. If the dataset contains no human clinical evidence, the request lacks a central criterion; stronger nonclinical language cannot repair it.
Build the argument around the observed clinical signal
An RMAT request should let the reviewer trace the proposed benefit back to the actual clinical evidence. Start with the unmet medical need, then show what the observed signal contributes and what it cannot yet establish.
| Argument | Evidence to present | Limitation to keep visible |
|---|---|---|
| Eligible product | Product identity and rationale for the regenerative-medicine definition | An advanced-therapy label does not itself establish eligibility |
| Serious condition | Disease course, serious manifestations and intended treatment effect | A broad disease name may conceal a different severity or population |
| Unmet medical need | Available therapies, their benefits/risks and remaining need | An absence of a cure is not the whole treatment-landscape analysis |
| Clinical signal | Patient counts, treatment exposure, endpoint definitions and actual outcomes | Missing assessments, selected evaluable subsets and short follow-up |
| Credibility | Study design, collection methods, sites and analysis | Bias, confounding and limitations of any historical comparison |
| Relevance to development product | Product used in the evidence and intended clinical product | Manufacturing changes or product differences need an explicit comparability assessment |
| Safety and durability | Relevant adverse findings and duration of observation | Early improvement is not proof of durable benefit or established safety |
The February 2019 guidance does not require a universal minimum patient count or a concurrent-control trial for every request. It describes potentially informative historical-control studies, well-designed retrospective studies and systematically collected case series, including evidence from outside the United States. Explain why the particular evidence is credible for this product and condition; do not treat the existence of one of those study types as an automatic qualification.
Fictional evidence exercise: 12 patients receive the product, nine have the planned assessment available and seven meet the prespecified response definition at that time point. A draft reports “78% durable response” without mentioning the three missing assessments or limited follow-up. State the treated population, assessment availability, response count and observation period. Explain missingness and use the appropriate prespecified analysis population. Do not silently remove missing patients, automatically assign them an outcome without an analysis basis, or add durability that the follow-up does not establish.
Map each claim in the summary to the report location, dataset cutoff and product version. FDA's guidance emphasizes that the preliminary evidence should be generated with the product intended for clinical development, while noting that manufacturing changes do not necessarily preclude designation and require case-by-case consideration. Describe a relevant change and the supporting comparability information instead of either ignoring it or declaring automatic ineligibility.
Keep RMAT and breakthrough therapy criteria distinct. The guidance says RMAT does not require evidence of potential substantial improvement over available therapies in the way breakthrough therapy designation does. RMAT still requires preliminary clinical evidence of potential to address an unmet medical need. A strong nonclinical result alone does not satisfy that clinical-evidence criterion.
Confirm IND status and the submission handoff. The final guidance addresses inactive INDs as well as clinical holds: it says CBER will not accept requests for INDs in those states and will not further process a pending request if the IND becomes inactive or is placed on hold during review. FDA describes a response within 60 calendar days of receipt. Record the actual decision rather than treating the passage of that interval as designation.
Use the clinical overview to keep the broader benefit-risk account consistent and the submission cover letter to make the requested action clear. A Fast Track request or orphan designation request requires its own criteria and supporting narrative.
Your preparation checklist
0/3 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Can nonclinical evidence alone support RMAT designation?
The designation criteria include preliminary clinical evidence of potential to address an unmet medical need for a serious condition. Nonclinical findings can support biological plausibility, but they do not replace that criterion. Describe the actual human evidence and its limitations rather than amplifying a mechanism claim to fill the gap.
Is there a fixed minimum trial size or randomized-trial requirement for RMAT?
The guidance does not set a universal minimum patient count or require a concurrent-control trial in every case. FDA evaluates factors such as rigor, outcomes, sample size, sites, disease context and bias. Explain why the available clinical evidence is persuasive for this particular product rather than claiming that any small case series qualifies.
Can clinical evidence from outside the United States support an RMAT request?
The final guidance says preliminary clinical evidence may come from studies outside the United States. Establish the relevance of the patients, product, administration, outcome assessment and data quality. The study location alone neither establishes sufficiency nor eliminates the need to explain limitations and applicability to the development program.
Does RMAT require the same substantial-improvement showing as breakthrough therapy designation?
No. The guidance distinguishes the criteria: RMAT concerns preliminary clinical evidence of potential to address unmet medical needs and does not require the breakthrough program’s potential substantial-improvement showing. That distinction does not remove the product, serious-condition or clinical-evidence criteria for RMAT.
What happens to an RMAT request when the IND is inactive or on clinical hold?
The final guidance says CBER will not accept requests for inactive INDs or INDs on clinical hold, and will not further process a pending request if that status arises during review. Verify the actual IND status and agency correspondence. A submitted request or elapsed review period is not proof that designation was granted.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
FDA resource
FDA Regenerative Medicine Advanced Therapy Designation ↗Current eligibility, IND and clinical-hold statements checked September 22, 2026.
Guidance
Expedited Programs for Regenerative Medicine Therapies for Serious Conditions ↗February 2019 final guidance; RMAT eligibility, preliminary clinical evidence and request content.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 1.12.18. A heading identifies placement, not mandatory applicability.